NCT04244578 is a NA clinical trial of Active tDCS in Dyslexia, sponsored by Bambino Gesù Hospital and Research Institute.

Who is sponsoring NCT04244578?

NCT04244578 is sponsored by Bambino Gesù Hospital and Research Institute.

What drugs are being tested in NCT04244578?

Interventions in NCT04244578: Active tDCS, Sham tDCS.

Is NCT04244578 still recruiting?

NCT04244578 is currently completed. Last updated 23 July 2021.

Last reviewed 2021-07-23 · How we verify

NCT04244578

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcranial Direct Current Stimulation in the Treatment of Dyslexia.

Completed NA Last updated 23 July 2021

What this trial tests

NA trial testing Active tDCS in Dyslexia in 28 participants. Completed in 1 February 2021.

Timeline

1 May 2016

Primary endpoint
1 September 2020

1 February 2021

Quick facts

Lead sponsor	Bambino Gesù Hospital and Research Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	28
Start date	1 May 2016
Primary completion	1 September 2020
Estimated completion	1 February 2021
Sites	1 location across Italy

Drugs / interventions tested

Active tDCS
Sham tDCS

Conditions studied

Dyslexia — all drugs for Dyslexia →

Sponsor

Bambino Gesù Hospital and Research Institute

Who can join

Adults 9 to 18, any sex, with Dyslexia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study grounds on the absence of evidence-based treatment in individuals with dyslexia. At this topic, the present study will explore the potential effect of transcranial direct current stimulation (tDCS) over parieto-occipital brain regions, cerebral areas usually disrupted in individuals with dyslexia. tDCS will be administered without concomitantly training. Therefore, the investigators hypothesized that active tDCS over parieto-occipital areas will enhance reading skills in children and adolescents with dyslexia. On the contrary, sham tDCS (placebo) over parieto-occipital areas will not have significant effect on reading. Further, both active and sham tDCS will be safe and well-tolerated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of a short and intensive transcranial direct current stimulation treatment in children and adolescents with developmental dyslexia: A crossover clinical trial.
Battisti A, Lazzaro G, Costanzo F, Varuzza C, et al · · 2022 · cited 16× · PMID 36160506 · DOI 10.3389/fpsyg.2022.986242

Verify or expand the search:

Other trials of Active tDCS

Trials testing the same drug.

NCT07246993 — Targeting Neuroplasticity for Persistent Post-Concussive Cognitive Symptoms · NA · recruiting
NCT07404319 — Effectiveness of Exercise Alone and tDCS+Exercise on Cognitive Function Improvement in Patients With Treatment Resistant · NA · not yet recruiting
NCT07212829 — The Added Value of Transcranial Direct Current Stimulation (tDCS) During Exercise for People With Chronic Widespread Pai · NA · not yet recruiting
NCT07202455 — Effect of Early Neuromodulation Coupled With Rehabilitation on the Prevention of Post-stroke Pain · NA · not yet recruiting
NCT06901687 — Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) · Phase 2 · recruiting

Other recruiting trials for Dyslexia

Currently open trials in the same condition.

NCT07262853 — Dual Executive Function Training Package · NA · recruiting
NCT06902610 — Examining the Medium-term Effect on Non Inferiority of the Previous Training With the DMD Poppins Clinical for Cognitive · recruiting
NCT05996497 — Evaluation of Speech Rhythm Training in Dyslexic Readers Aged 7 to 9 Years · NA · recruiting
NCT05780853 — A Game-based Neurodevelopmental Assessment for Young Children · recruiting
NCT03285789 — Dyslexics' Visual Attention Field · NA · active not recruiting

Other Bambino Gesù Hospital and Research Institute trials

Trials by the same sponsor.

NCT07297914 — Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL · Phase 2, PHASE3 · not yet recruiting
NCT07464561 — RESCCUE4 - Group CBT for Social Anxiety in Adolescents · NA · completed
NCT06080191 — Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL · Phase 1 · recruiting
NCT06064903 — CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL · Phase 1, PHASE2 · recruiting
NCT06931730 — Reprogramming Energy Homeostasis in Overweight Individuals Via Exercise, Cognitive, and Social Training · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04244578 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bambino Gesù Hospital and Research Institute
Last refreshed: 23 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04244578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing